| Acne and Rosacea Treatments and Effects | Lifetime | 35 | IT 2 | 98.92 |
| Chemotherapy-related skin toxicity | Lifetime | 29 | IT 3 | 98.40 |
| Dermatology and Skin Diseases | Lifetime | 169 | IT 6 | 98.99 |
| Dermatologic Treatments and Research | Lifetime | 93 | IT 4 | 98.74 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 15 | IT 2 | 98.29 |
| Skin Protection and Aging | Lifetime | 146 | IT 6 | 98.43 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 169 | IT 9 | 98.52 |
| Colorectal and Anal Carcinomas | Lifetime | 275 | IT 13 | 98.08 |
| Nonmelanoma Skin Cancer Studies | Lifetime | 181 | IT 15 | 97.93 |
| Hair Growth and Disorders | Lifetime | 112 | IT 4 | 97.26 |
| Dermatological and COVID-19 studies | Lifetime | 55 | IT 8 | 95.86 |
| melanin and skin pigmentation | Lifetime | 268 | IT 14 | 97.23 |
| Cutaneous Melanoma Detection and Management | Lifetime | 313 | IT 26 | 97.80 |
| Allergic Rhinitis and Sensitization | Lifetime | 834 | IT 45 | 96.98 |
| Cutaneous lymphoproliferative disorders research | Lifetime | 403 | IT 36 | 96.32 |
| Autoimmune Bullous Skin Diseases | Lifetime | 606 | IT 47 | 96.01 |
| Nail Diseases and Treatments | Lifetime | 663 | IT 37 | 95.35 |
| Autoimmune and Inflammatory Disorders | Lifetime | 518 | IT 46 | 93.24 |
| Dermatological and COVID-19 studies | 2021-2025 | 1 | IT 1 | 97.82 |
| Dermatology and Skin Diseases | 2021-2025 | 28 | IT 1 | 99.57 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 23 | IT 3 | 99.43 |
| Colorectal and Anal Carcinomas | 2021-2025 | 56 | IT 5 | 97.55 |
| Asthma and respiratory diseases | 2021-2025 | 126 | IT 15 | 98.80 |
| Chemotherapy-related skin toxicity | 2021-2025 | 8 | IT 2 | 96.55 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 100 | IT 11 | 98.36 |
| Acne and Rosacea Treatments and Effects | 2021-2025 | 23 | IT 1 | 97.23 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 16 | IT 4 | 97.74 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 76 | IT 13 | 97.12 |
| Cancer and Skin Lesions | 2021-2025 | 115 | IT 14 | 89.57 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 109 | IT 17 | 90.00 |
| Cutaneous lymphoproliferative disorders research | 2021-2025 | 218 | IT 32 | 90.65 |
| Pharmaceutical studies and practices | 2021-2025 | 297 | IT 15 | 86.93 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 98 | IT 11 | 82.43 |
| melanin and skin pigmentation | 2021-2025 | 231 | IT 16 | 85.84 |
| Dermatologic Treatments and Research | 2021-2025 | 317 | IT 28 | 88.03 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 300 | IT 51 | 88.45 |
| Drug-Induced Adverse Reactions | 2021-2025 | 216 | IT 15 | 87.72 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 608 | IT 74 | 88.14 |
| Hair Growth and Disorders | 2021-2025 | 183 | IT 6 | 86.60 |
| Parvovirus B19 Infection Studies | 2021-2025 | 174 | IT 17 | 82.64 |
| Urticaria and Related Conditions | 2021-2025 | 420 | IT 33 | 86.44 |
| Skin Diseases and Diabetes | 2021-2025 | 79 | IT 10 | 79.49 |
| Contact Dermatitis and Allergies | 2021-2025 | 320 | IT 25 | 84.80 |
| Skin Protection and Aging | 2021-2025 | 778 | IT 38 | 76.01 |
| Nail Diseases and Treatments | 2021-2025 | 700 | IT 48 | 74.72 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 803 | IT 80 | 73.97 |
| Genetic and rare skin diseases. | 2021-2025 | 263 | IT 24 | 65.50 |
